Annual report pursuant to Section 13 and 15(d)

Subsequent Events

Subsequent Events
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
On January 3, 2023, the Company announced that it had entered into a settlement agreement with Sun to file a joint motion to terminate the ongoing IPR and to settle the ongoing patent infringement litigation in the United States related to Sun's CEQUA product. The settlement agreement was contingent on receipt of termination of the IPR by the USPTO in respect of our '036 patent.
On January 24, 2023, the Company announced that the USPTO allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. This newly allowed patent application reflects the unique and proprietary dosing regimen of LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with MMF and corticosteroids using eGFR as a method of pharmacodynamically dosing LUPKYNIS in patients with LN. The newly allowed application provides patent coverage that supplements our existing ‘036 patent. The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label. This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037. The Company intends to list this newly allowed patent in the Orange Book once issued.
On January 25, 2023, the USPTO terminated the IPR it had instituted with respect to Aurinia's '036 patent.